ArticleNPJ cardiovascular health2025
Collagen-targeted tracers for molecular imaging of atrial fibrosis and sensitive detection of atrial fibrillation.
Article in NPJ cardiovascular health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Atrial fibrillation (AF), often accompanied by atrial fibrosis, is challenging to diagnose sub-clinically and reverse once established. Molecular imaging targeting excess atrial collagen may enable earlier detection of atrial fibrosis and its associated arrhythmias. We used the collagen I-binding peptide EP-3533 and our novel 'T-peptide' targeting matrix metalloproteinases-2-digested collagen IV to image interstitial atrial fibrosis, AF and heart failure (HF) that develop in the double transgenic mouse model dnPI3K-Mst1 (termed 'AF + HF'). Ex vivo and in vivo imaging were performed using near-infrared scans and positron emission tomography (PET) with probes conjugated to Cyanine5.5 and copper-64, respectively. Both tracers significantly accumulated in fibrotic atria compared to non-transgenic controls, with specific T-peptide uptake relative to a mutated 'S-peptide'. Pharmacokinetic profiling demonstrated good tracer plasma stability and fast renal clearance. These results highlight the potential of collagen-targeted peptide tracers, particularly the disease stage-sensitive T-peptide, to improve diagnosis and monitoring of atrial fibrosis and AF.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.